Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Myelodysplastic syndromes (MDS) are a group of disorders characterized by variable cytopenias and ineffective hematopoiesis. Hematopoietic stem cells (HSCs) and myeloid progenitors in MDS have not been extensively characterized. We transplanted purified human HSCs from MDS samples into immunodeficient mice and show that HSCs are the disease-initiating cells in MDS. We identify a recurrent loss of granulocyte-macrophage progenitors (GMPs) in the bone marrow of low risk MDS patients that can distinguish low risk MDS from clinical mimics, thus providing a simple diagnostic tool. The loss of GMPs is likely due to increased apoptosis and increased phagocytosis, the latter due to the up-regulation of cell surface calreticulin, a prophagocytic marker. Blocking calreticulin on low risk MDS myeloid progenitors rescues them from phagocytosis in vitro. However, in the high-risk refractory anemia with excess blasts (RAEB) stages of MDS, the GMP population is increased in frequency compared with normal, and myeloid progenitors evade phagocytosis due to up-regulation of CD47, an antiphagocytic marker. Blocking CD47 leads to the selective phagocytosis of this population. We propose that MDS HSCs compete with normal HSCs in the patients by increasing their frequency at the expense of normal hematopoiesis, that the loss of MDS myeloid progenitors by programmed cell death and programmed cell removal are, in part, responsible for the cytopenias, and that up-regulation of the "don't eat me" signal CD47 on MDS myeloid progenitors is an important transition step leading from low risk MDS to high risk MDS and, possibly, to acute myeloid leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both myelodysplastic syndrome (Pang et al., 2013) and acute and chronic myelogenous leukemias begin with nonlethal mutations in the HSC pool, often leading to successful expansion of mutant HSC clones at the expense of normal HSC, and which progress eventually to leukemia (Corces-Zimmerman et al., 2014; Jamieson et al., 2004; Jan et al., 2012)”
From Quiescent Hematopoietic Stem Cells Accumulate DNA Damage during Aging that Is Repaired upon Entry into Cell Cycle (2014) · cites this paper as Pang et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Self-citationInternational scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427 · cited 1×
“Cells 20(2-3):364–369, discussion 369–370.”
Self-citationRevised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 2,844
Self-citationCD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,581
Self-citationGranulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485 · cited 2×
“Jamieson CH, et al. (2004) Granulocyte-macrophage progenitors as candidate leuke- mic stem cells in blast-crisis CML.”
BackgroundSelf-citationGardai, S. J., McPhillips, K. A., Frasch, S. C., Janssen, W. J., Starefeldt, A., Murphy-Ullrich, J. E., Bratton, D. L., Oldenborg, P.-A., Michalak, M., & Henson, P. M. (2005) · Cell · doi:10.1016/j.cell.2005.08.032 · Cited by 1,473
McCune, J., Namikawa, R., Kaneshima, H., Shultz, L., Lieberman, M., & Weissman, I. (1988) · Science · doi:10.1126/science.241.4873.1632 · Cited by 1,406
Self-citationChao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087
Self-citationIsolation of a candidate human hematopoietic stem-cell population.
Baum, C. M., Weissman, I. L., Tsukamoto, A. S., Buckle, A. M., & Peault, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2804 · Cited by 1,086
Self-citationHuman bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age
Pang, W. W., Price, E. A., Sahoo, D., Beerman, I., Maloney, W. J., Rossi, D. J., Schrier, S. L., & Weissman, I. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116110108 · Cited by 991 · cited 3×
“The use of age-matched controls is crucial in studies such as this, because most patients with MDS are elderly, and normal bone marrow changes with age, with increased frequency of immunophenotypic HSCs in normal elderly bone marrow compared with young (30).”
BackgroundInfluentialSelf-citationDevelopment of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice
Ishikawa, F., Yasukawa, M., Lyons, B., Yoshida, S., Miyamoto, T., Yoshimoto, G., Watanabe, T., Akashi, K., Shultz, L. D., & Harada, M. (2005) · Blood · doi:10.1182/blood-2005-02-0516 · Cited by 932
Stems Cells and the Pathways to Aging and Cancer
Rossi, D. J., Jamieson, C. H. M., & Weissman, I. L. (2008) · Cell · doi:10.1016/j.cell.2008.01.036 · Cited by 895
Self-citationPurification of primitive human hematopoietic cells capable of repopulating immune-deficient mice
Bhatia, M., Wang, J. C. Y., Kapp, U., Bonnet, D., & Dick, J. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5320 · Cited by 850
Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776 · cited 4×
“In addition, blocking CD47 ligation of its receptor SIRPα allows for the prophagocytic cell surface CRT to signal phagocytosis and clearance of tumor cells (18).”
BackgroundInfluentialSelf-citationClonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia
Jan, M., Snyder, T. M., Corces-Zimmerman, M. R., Vyas, P., Weissman, I. L., Quake, S. R., & Majeti, R. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004315 · Cited by 721
Self-citationChan, K. S., Espinosa, I., Chao, M., Wong, D., Ailles, L., Diehn, M., Gill, H., Presti, J., Chang, H. Y., van de Rijn, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906549106 · Cited by 660
Self-citationIdentification of a Hierarchy of Multipotent Hematopoietic Progenitors in Human Cord Blood
Majeti, R., Park, C. Y., & Weissman, I. L. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.10.001 · Cited by 602
Self-citationProspective isolation of human clonogenic common myeloid progenitors
Manz, M. G., Miyamoto, T., Akashi, K., & Weissman, I. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172384399 · Cited by 534 · cited 2×
“We evaluated by flow cytometry the distribution and frequency of immunophenotypic common myeloid progenitors (CMPs; LinCD34CD38CD123 CD45RA), granulocyte-macrophage progenitors (GMPs; LinCD34CD38CD123CD45RA), and megakaryocyte-erythroid progenitors (MEPs; LinCD34CD38CD123CD45RA) (8) in low riskMDS and normal bonemarro…”
BackgroundSelf-citationMiyamoto, T., Weissman, I. L., & Akashi, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7521 · Cited by 465
Self-citationTherapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C. Y., Weissman, I. L., & Majeti, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2238 · Cited by 382
Self-citationUchida, N., Sutton, R. E., Friera, A. M., He, D., Reitsma, M. J., Chang, W. C., Veres, G., Scollay, R., & Weissman, I. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11939 · Cited by 295 · cited 1×
“Proc Natl Acad Sci USA 89(7):2804–2808.”
Self-citationJamieson, C. H. M., Gotlib, J., Durocher, J. A., Chao, M. P., Mariappan, M. R., Lay, M., Jones, C., Zehnder, J. L., Lilleberg, S. L., & Weissman, I. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601462103 · Cited by 286
Self-citationbcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages.
Lagasse, E., & Weissman, I. L. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.1047 · Cited by 274 · cited 1×
“Here, we show that low risk MDS likely follow this progression toward high risk MDS and reveal a stage wherein the preleukemic HSC clones outcompete normal HSC clones, but, at their oligolineage progenitor stage, lose blood-forming capacity as a result of programmed cell death and programmed cell removal (37, 42), res…”
BackgroundSelf-citationPersistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission
Tehranchi, R., Woll, P. S., Anderson, K., Buza-Vidas, N., Mizukami, T., Mead, A. J., Åstrand-Grundström, I., Strömbeck, B., Horvat, A., Ferry, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912228 · Cited by 253 · cited 1×
“HSCs from MDS patients (MDS HSCs) are relatively resistant to lenalidomide and decitabine treatment, because even patients with cytogenetic remission, as determined by FISH on peripheral blood cells, can maintain a significant MDS HSC burden (12, 13).”
BackgroundGlycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation
Abrahamsson, A. E., Geron, I., Gotlib, J., Dao, K.-H. T., Barroga, C. F., Newton, I. G., Giles, F. J., Durocher, J., Creusot, R. S., Karimi, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900189106 · Cited by 246
Self-citationProgrammed cell removal: a new obstacle in the road to developing cancer
Chao, M. P., Majeti, R., & Weissman, I. L. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3171 · Cited by 245 · cited 2×
“Here, we show that low risk MDS likely follow this progression toward high risk MDS and reveal a stage wherein the preleukemic HSC clones outcompete normal HSC clones, but, at their oligolineage progenitor stage, lose blood-forming capacity as a result of programmed cell death and programmed cell removal (37, 42), res…”
BackgroundSelf-citationvan de Loosdrecht, A. A., Alhan, C., Bene, M. C., Della Porta, M. G., Drager, A. M., Feuillard, J., Font, P., Germing, U., Haase, D., Homburg, C. H., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.005801 · Cited by 239
Will, B., Zhou, L., Vogler, T. O., Ben-Neriah, S., Schinke, C., Tamari, R., Yu, Y., Bhagat, T. D., Bhattacharyya, S., Barreyro, L., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399683 · Cited by 238 · cited 3×
“A recent study has shown a relative increase in CMP frequency in MDS (13).”
BackgroundAltered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
Rajapaksa, R., Ginzton, N., Rott, L., & Greenberg, P. (1996) · Blood · doi:10.1182/blood.v88.11.4275.4275 · Cited by 192
Self-citationShetty, V., Mundle, S., Alvi, S., Showel, M., Broady-Robinson, L., Dar, S., Borok, R., Showel, J., Gregory, S., Rifkin, S., et al. (1996) · Leukemia Research · doi:10.1016/s0145-2126(96)00008-2 · Cited by 177
Orr, A. W., Pedraza, C. E., Pallero, M. A., Elzie, C. A., Goicoechea, S., Strickland, D. K., & Murphy-Ullrich, J. E. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302069 · Cited by 167 · cited 1×
“Proc Natl Acad Sci USA 95(20):11939–11944.”
Negrin, R. S., Atkinson, K., Leemhuis, T., Hanania, E., Juttner, C., Tierney, K., Hu, W. W., Johnston, L. J., Shizuru, J. A., Stockerl-Goldstein, K. E., et al. (2000) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(00)70008-5 · Cited by 167
Self-citationNilsson, L., Åstrand-Grundström, I., Anderson, K., Arvidsson, I., Hokland, P., Bryder, D., Kjeldsen, L., Johansson, B., Hellström-Lindberg, E., Hast, R., et al. (2002) · Blood · doi:10.1182/blood-2001-12-0188 · Cited by 163
Stem Cell Research: Paths to Cancer Therapies and Regenerative Medicine
Weissman, I. (2005) · JAMA · doi:10.1001/jama.294.11.1359 · Cited by 152
Self-citationEvidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome
Sternberg, A. (2005) · Blood · doi:10.1182/blood-2005-04-1543 · Cited by 140 · cited 1×
“Because MDS prevalence increases with age, it is possible that the bias of normal elderly HSCs away from lymphoid differentiation predisposes them to develop into MDS HSCs, which we have shown to exhibit even poorer generation of lymphoid progeny, a phenotype that has been described in human MDS patients (33).”
BackgroundHofmann, W., & Koeffler, H. P. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104704 · Cited by 129
Nilsson, L., Edén, P., Olsson, E., Månsson, R., Åstrand-Grundström, I., Strömbeck, B., Theilgaard-Mönch, K., Anderson, K., Hast, R., Hellström-Lindberg, E., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079368 · Cited by 112 · cited 1×
“Previously, it has been shown that the HSC compartment in MDS is enriched for cytogenetically abnormal cells, including in two MDS samples with monosomy 7 (10, 11, 13).”
BackgroundMundle, S. D., Venugopal, P., Cartlidge, J., Pandav, D., Broady-Robinson, L., Gezer, S., Robin, E., Rifkin, S., Klein, M., Alston, D., et al. (1996) · Blood · doi:10.1182/blood.v88.7.2640.bloodjournal8872640 · Cited by 86
Park, C. Y., Majeti, R., & Weissman, I. L. (2008) · Nature Protocols · doi:10.1038/nprot.2008.194 · Cited by 56
Self-citationRaza, A., Alvi, S., Broady-Robinson, L., Showel, M. M., Cartlidge, J., Sd, M., Shetty, V. T., Borok, R. Z., Se, D., Hk, C., et al. (1997) · PubMed · Cited by 33
Analysis of human hematopoietic stem cell populations.
Murray, L. J., DiGiusto, D. L., Chen, B., Chen, S., Combs, J., Conti, A., Galy, A. H. M., Negrin, R. S., Tricot, G. J. K., & Tsukamoto, A. S. (1994) · PubMed · Cited by 33
Péault, B., Weissman, I. L., Buckle, A., Tsukamoto, A. S., & Baum, C. M. (1993) · PubMed · Cited by 29
Self-citation
Research works printed but not linked: 1
- Brunning R, et al. (2008) Myelodysplastic syndromes/neoplasms. WHO Classification of Tumours and Haematopoietic and Lymphoid Tissues, eds Swerdlow S, et al. (Intl Agency Res Cancer, Lyon, France), Vol 2.
Cited by
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756
Phagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y.-X., & Weissman, I. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0183-z · Cited by 911
Self-citationCD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
Kojima, Y., Volkmer, J.-P., McKenna, K., Civelek, M., Lusis, A. J., Miller, C. L., Direnzo, D., Nanda, V., Ye, J., Connolly, A. J., et al. (2016) · Nature · doi:10.1038/nature18935 · Cited by 683
“…signalling associated with programmed cell removal; viable myelo-dysplastic syndrome haematopoietic oligolineage progenitors express the phagocytic signal calreticulin, but not CD47, whereas acute myeloid leukaemia derived from myelodysplastic syndromes are positive for CD47 expression 24 .”
BackgroundSelf-citationCD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J.-P., Liu, J., Lim, J. S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81603 · Cited by 444
“In addition, calreticulin has been identified as one such prophagocytic signal and may play particular importance in the malignant conversion of myelodysplastic syndrome to acute myelogenous leukemia (45, 46).”
BackgroundSelf-citationBeerman, I., Seita, J., Inlay, M. A., Weissman, I. L., & Rossi, D. J. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.04.016 · Cited by 445
“Both myelodysplastic syndrome (Pang et al., 2013) and acute and chronic myelogenous leukemias begin with nonlethal mutations in the HSC pool, often leading to successful expansion of mutant HSC clones at the expense of normal HSCs and that eventually progress to leukemia (Corces- Zimmerman et al.,…”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Pang, W. W., Pluvinage, J. V., Price, E. A., Sridhar, K., Arber, D. A., Greenberg, P. L., Schrier, S. L., Park, C. Y., & Weissman, I. L.
- Affiliations
- Institute for Stem Cell Biology and Regenerative Medicine (IN)
- Stanford Medicine (US)
- Departments of bPathology and
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-02-06
- Volume
- 110
- Issue
- 8
- Pages
- 3011-3016
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3581956
- OpenAlex
- W2126448969
- Cited by
- 277
- References
- 42
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 23 · 2023: 25 · 2022: 23 · 2021: 29 · 2020: 33 · 2019: 13 · 2018: 13 · 2017: 22 · 2016: 28 · 2015: 21 · 2014: 17 · 2013: 14
- FWCI
- 19.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (W81XWH-11-1-, W81XWH)
- Leukemia and Lymphoma Society
- National Institutes of Health (W81XWH)
- National Institute on Aging (R01AG029124)
- National Cancer Institute (R01 CA86065, K08CA1295470, R01CA086065, K08CA129547, P01CA139490, R01CA086017)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- myelodysplastic syndrome, hematopoietic stem cells, myeloid progenitor cells, CFU-GM, calreticulin, CD47, phagocytosis, apoptosis, refractory anemia with excess blasts, acute myeloid leukemia, bone marrow transplantation, ineffective hematopoiesis
- MeSH terms
- Animals, Hematopoietic Stem Cells, Humans, Myelodysplastic Syndromes, Phagocytosis, Antigens, CD, In Situ Hybridization, Fluorescence, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.